IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Exclusion Criteria

• •1. Autologous HSCT within 100 days prior to first administration, or any prior allogeneic HSCT or solid organ transplantation.
• •2. History of central nervous system (CNS) metastases or active CNS involvement.
• •3. History of other malignancy within the past 5 years.
• •4. Severe organic cardiovascular or cerebrovascular diseases.
• •5. History of severe allergic reactions to any components of the trial drug, any macromolecular protein preparations or monoclonal antibodies.
• •6. Previous treatment with anti-CD47 monoclonal antibody/SIRPα fusion protein.
• •7. Human immunodeficiency virus (HIV) infection.
• •8. Echocardiography examination indicating left ventricular ejection fraction (LVEF) \< 55%.
• •9. Active infection requiring systemic therapy (e.g., fungal, bacterial, viral).